Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - flucloxacillin, quantity: 500 mg - injection, powder for - excipient ingredients: - treatment of confirmed or suspected staphylococcal infections and other gram-positive coccal infections including pneumonia, skin and skin structure and wound infections, infected burns and cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - flucloxacillin sodium monohydrate, quantity: 2176 mg (equivalent: flucloxacillin, qty 2000 mg) - injection, powder for - excipient ingredients: - treatment of confirmed or suspected staphylococcal infections and other gram-positive coccal infections including pneumonia, skin and skin structure and wound infections, infected burns and cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - flucloxacillin sodium monohydrate, quantity: 1088.1 mg (equivalent: flucloxacillin, qty 1000 mg) - injection, powder for - excipient ingredients: - for the treatment of confirmed or suspected staphylococcal infections and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and skin structure and wound infections, infected burns and cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - flucloxacillin sodium monohydrate, quantity: 544.1 mg (equivalent: flucloxacillin, qty 500 mg) - injection, powder for - excipient ingredients: - for the treatment of confirmed or suspected staphylococcal infections and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and skin structure and wound infections, infected burns and cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited t/a radpharm scientific - stannous chloride dihydrate, quantity: 0.24 mg; disofenin, quantity: 20 mg - injection, powder for - excipient ingredients: - indications as at 14 may 2003: technetium tc99m disofenin is indicated as an adjunct in the diagnosis of hepatobiliary disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin sodium, quantity: 1.06 g (equivalent: amoxicillin, qty 1 g) - injection, powder for - excipient ingredients: - amoxil parenteral is intended for use where the patient's condition precludes the administration of the oral form. it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. septicaemia: (bacterial) h. influenzae; e. coli (see microbiology); p.mirabilis; streptococcus; s. pneumoniae; s. faecalis and salmonella typhi. skin and skin structure: staphylococcus, non-penicillinase-producing; streptococcus; e. coli (see microbiology). respiratory, acute and chronic: haemophilus influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase producing; e. co

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amoxicillin sodium, quantity: 530.1 mg; potassium clavulanate, quantity: 119.13 mg - injection, powder for - excipient ingredients: - amoxiclav juno is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav juno treatment due to its amoxicillin content. infections caused by ?-lactamase producing amoxicillin resistant organisms are also amenable to amoxiclav juno due to its clavulanic acid content. susceptibility to amoxiclav juno will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. amoxiclav juno is indicated for the short term treatment of serious bacterial infections such as: ? ? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms ? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia ? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, , female genital infections ? gastrointestinal infections ? e.g. intra-abdominal sepsis, peritonitis. ? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess ? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections. ? ? amoxiclav juno is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastronitestinal surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amoxicillin sodium, quantity: 1060.2 mg (equivalent: amoxicillin, qty 1000 mg); potassium clavulanate, quantity: 238.25 mg (equivalent: clavulanic acid, qty 200 mg) - injection, powder for - excipient ingredients: - amoxiclav juno is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav juno treatment due to its amoxicillin content. infections caused by ?-lactamase producing amoxicillin resistant organisms are also amenable to amoxiclav juno due to its clavulanic acid content. susceptibility to amoxiclav juno will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. amoxiclav juno is indicated for the short term treatment of serious bacterial infections such as: ? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms ? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia ? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, , female genital infections ? gastrointestinal infections ? e.g. intra-abdominal sepsis, peritonitis. ? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess ? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections. ? amoxiclav juno is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastronitestinal surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amoxicillin sodium, quantity: 2120.4 mg; potassium clavulanate, quantity: 238.25 mg - injection, powder for - excipient ingredients: - amoxiclav juno is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav juno treatment due to its amoxicillin content. infections caused by ?-lactamase producing amoxicillin resistant organisms are also amenable to amoxiclav juno due to its clavulanic acid content. susceptibility to amoxiclav juno will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. amoxiclav juno is indicated for the short term treatment of serious bacterial infections such as: ? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms ? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia ? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, , female genital infections ? gastrointestinal infections ? e.g. intra-abdominal sepsis, peritonitis. ? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess ? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections. ? amoxiclav juno is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastronitestinal surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amoxicillin, quantity: 1 g - injection, powder for - excipient ingredients: - ibiamox is intended for use where the patient?s condition precludes the administration of the oral form of amoxicillin. it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms.,note: therapy should be guided by bacteriological studies, including sensitivity tests, and clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxicillin sodium may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,septicaemia: (bacterial) h. influenzae; e. coli (see section 5.1 pharmacodynamic properties - microbiology); p. mirabilis; streptococcus; strep. pneumoniae; strep. faecalis and salmonella typhi.,skin and skin structure: staphylococcus (non-penicillinase-producing), streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology).,respiratory, acute and chronic: h. influenzae; streptococcus; strep. pneumoniae; staphylococcus (non-penicillinase producing); e. coli (see section 5.1 pharmacodynamic properties - microbiology).,genitourinary tract (complicated and uncomplicated), acute and chronic: e. coli (see section 5.1 pharmacodynamic properties - microbiology); p. mirabilis and strep. faecalis.,gonorrhoea: n. gonorrhoeae (nonpenicillinase producing),prophylaxis of endocarditis: amoxicillin sodium may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with prosthetic heart valves or those who have previously had endocarditis.